Viral Genetics Identifies Crucial Peptides for Potential HIV/AIDS Drug

Jan 09, 2007, 00:00 ET from Viral Genetics, Inc.

    AZUSA, Calif., Jan. 9 /PRNewswire-FirstCall/ -- Viral Genetics (OTC
 Bulletin Board: VRAL) has identified two key peptides involved in its
 thymus nuclear protein or "TNP" technology currently under development for
 the treatment of HIV/AIDS. The active components of VGV-1, Viral Genetics'
 lead drug candidate based on TNP, were discovered by independent research
 laboratories and additional studies to confirm these findings are currently
     The compounds identified include two classes of peptides (small protein
 fragments) that occur naturally in a variety of mammals, including humans.
 While both have been studied and reported in the scientific literature
 predominantly as markers, their therapeutic uses have not been actively
 pursued to date.
     In published studies, one of the peptides has been characterized as an
 immune modulator, possibly possessing natural antiviral and anti-infective
 properties. Researchers have also identified an association between levels
 of this peptide and certain viral infections and cancers.
     "From a scientific perspective, this may be a very important discovery
 for Viral Genetics and, if confirmed, could shed insight into our
 understanding of TNP and VGV-1. By having the active components isolated,
 we should be able to identify the mechanism of action and determine optimal
 dose. These are critical requirements in the process of improving the
 antiviral effects of the product and moving towards US clinical trials,"
 said Dr. Eric Rosenberg, Chairman of the Company's scientific advisory
 board and Associate Professor of Medicine at Harvard Medical School.
     "While these results are preliminary and we are working rapidly to
 confirm them, this is a significant milestone for Viral Genetics and could
 greatly accelerate our development efforts in the United States and
 worldwide. Our hope is that the broad body of existing knowledge on the
 active compounds in the literature may also enhance our drug development
 pipeline," said Haig Keledjian, president and CEO of Viral Genetics, Inc.
     In recent studies, a reduction of HIV viral load was observed in a
 subset of patients after treatment with VGV-1 versus patients receiving
 placebo. As reported in the Company's poster presentation at the 2006 XVI
 International AIDS Conference, VGV-1 treated subjects also demonstrated
 apparent beneficial immunological changes when compared with placebo.
     The World Health Organization estimates approximately 40 million people
 are now living with HIV. Even with the available treatments for AIDS, there
 are large numbers of people that need alternative therapies and hope
 remains that progress will be made in discovering new therapies that
 bolster patients' immune systems.
     About VGV-1
     VGV-1 is a therapy based on thymus nuclear protein which is extracted
 from bovine thymus tissue. As a type of immune-based therapy, it focuses on
 boosting the immune system to allow the body to fight HIV more efficiently.
 Thymus nuclear protein technology has been studied in five human clinical
 trials for the treatment of HIV infection and AIDS.
     About Viral Genetics
     Viral Genetics, Inc. is a biotechnology company that discovers and
 develops immune-based therapies for HIV and AIDS using its thymus nuclear
 protein compound. This compound may have other potential applications for
 other infectious, autoimmune, and immunological deficiency diseases that
 the company intends to study in the future. Viral Genetics believes that
 VGV-1 represents a significant and unique approach to treating HIV due to
 the apparently novel mechanism, low toxicity profile, simple dosing
 regimen, and short-course of treatment. Online at
     For additional information, please contact Viral Genetics at
     This news release contains forward-looking statements that involve
 risks and uncertainties associated with clinical development, regulatory
 approvals, and other risks described by Viral Genetics, Inc. from time to
 time in its periodic reports filed with the SEC. VGV-1 is not approved by
 the US Food and Drug Administration or by any comparable regulatory
 agencies elsewhere in the world. While Viral Genetics believes that the
 forward-looking statements and underlying assumptions contained therein are
 reasonable, any of the assumptions could be inaccurate, including, but not
 limited to, the ability of Viral Genetics to establish the efficacy of
 VGV-1 in the treatment of any disease or health condition and the
 development of studies and strategies leading to commercialization of VGV-1
 in the United States. Therefore, there can be no assurance that the
 forward-looking statements included in this release will prove to be
 accurate. In light of the significant uncertainties inherent in the
 forward-looking statements included herein, the forward- looking statements
 should not be regarded as a representation by Viral Genetics or any other
 person that the objectives and plans of Viral Genetics will be achieved.

SOURCE Viral Genetics, Inc.